市場調査レポート
商品コード
250308

中枢神経系の提携の世界市場:取引動向、企業、財務状況

Central Nervous System Collaboration and Licensing Deals 2016-2023

出版日: | 発行: Current Partnering | ページ情報: 英文 650+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円
中枢神経系の提携の世界市場:取引動向、企業、財務状況
出版日: 2023年10月01日
発行: Current Partnering
ページ情報: 英文 650+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、1,500以上の中枢神経系 (CNS) の取引について調査分析し、利用可能な取引・契約書を対象に、取引動向や詳細データについて、体系的な情報を提供しています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 中枢神経系の取引における動向

  • イントロダクション
  • 長年にわたる中枢神経系の提携
  • 中枢神経系の提携:取引タイプ別
  • 中枢神経系の提携:産業部門別
  • 中枢神経系の提携:開発段階別
  • 中枢神経系の提携:技術タイプ別
  • 中枢神経系の提携:治療適応別

第3章 中枢神経系の提携に対する金融取引条件

  • イントロダクション
  • 中枢神経系の提携に対する財務状況の開示
  • 中枢神経系の提携における見出し値
  • 中枢神経系の取引における前払い
  • 中枢神経系の取引における目標達成報奨金
  • 中枢神経系のロイヤリティ料率

第4章 主要な中枢神経系の取引と取引業者

  • イントロダクション
  • 中枢神経系の提携で最も活発
  • 中枢神経系で最も活発な取引業者のリスト
  • 主要な中枢神経系の取引:金額別

第5章 中枢神経系の契約書ディレクトリ

  • イントロダクション
  • 利用可能な契約書における中枢神経系の提携取引

第6章 中枢神経系の取引:治療標的別

  • イントロダクション
  • 取引:治療標的別

付録

目次
Product Code: CP2203

Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of central nervous system deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in central nervous system dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the central nervous system field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in central nervous system dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of central nervous system deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of central nervous system deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse central nervous system collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Central Nervous System Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of central nervous system trends and structure of deals entered into by leading biopharma companies worldwide.

Central Nervous System Collaboration and Licensing Deals includes:

  • Trends in central nervous system dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of central nervous system deal records covering pharmaceutical and biotechnology
  • The leading central nervous system deals by value
  • Most active central nervous system licensing dealmakers

In Central Nervous System Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Central Nervous System Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse central nervous system collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

  • 2.1. Introduction
  • 2.2. Central nervous system partnering over the years
  • 2.3. Central nervous system partnering by deal type
  • 2.4. Central nervous system partnering by industry sector
  • 2.5. Central nervous system partnering by stage of development
  • 2.6. Central nervous system partnering by technology type
  • 2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for central nervous system partnering
  • 3.3. Central nervous system partnering headline values
  • 3.4. Central nervous system deal upfront payments
  • 3.5. Central nervous system deal milestone payments
  • 3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in central nervous system partnering
  • 4.3. List of most active dealmakers in central nervous system
  • 4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory

  • 5.1. Introduction
  • 5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by central nervous system therapeutic target
  • Deal Directory
  • Deal Directory - Central nervous system deals by company A-Z 2016 to 2023
  • Deal Directory - Central nervous system deals by technology type 2016 to 2023
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Central nervous system partnering since 2016
  • Figure 2: Central nervous system partnering by deal type since 2016
  • Figure 3: Central nervous system partnering by industry sector since 2016
  • Figure 4: Central nervous system partnering by stage of development since 2016
  • Figure 5: Central nervous system partnering by technology type since 2016
  • Figure 6: Central nervous system partnering by indication since 2016
  • Figure 7: Central nervous system deals with a headline value
  • Figure 8: Central nervous system deals with upfront payment values
  • Figure 9: Central nervous system deals with milestone payment
  • Figure 10: Central nervous system deals with royalty rates
  • Figure 11: Active central nervous system dealmaking activity since 2016
  • Figure 12: Top central nervous system deals by value since 2016